|
|
| | MK 6096 Basic information |
| Product Name: | MK 6096 | | Synonyms: | Filorexant;MK 6096;MK6096;MK-6096;((2R,5R)-5-(((5-Fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone MK6096;[(2R,5R)-5-[[(5-Fluoro-2-pyridinyl)oxy]methyl]-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]methanone;MK 6096;MK6096;CS-1825 | | CAS: | 1088991-73-4 | | MF: | C24H25FN4O2 | | MW: | 420.48 | | EINECS: | | | Product Categories: | | | Mol File: | 1088991-73-4.mol |  |
| | MK 6096 Chemical Properties |
| Boiling point | 540.2±50.0 °C(Predicted) | | density | 1.203±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:4): 0.2mg/mL; DMSO: 2mg/mL; Ethanol: 5mg/mL | | form | A solid | | pka | 1.54±0.22(Predicted) | | color | Off-white to brown |
| | MK 6096 Usage And Synthesis |
| Description | Filorexant is a dual antagonist of orexin 1 receptor (OX1R) and OX2R (Kis = 2.5 and 0.31 nM, respectively, for the recombinant human receptors). It selectively inhibits OX1R and OX2R over a panel of more than 170 receptors and enzymes. Filorexant inhibits orexin A-induced calcium mobilization in CHO cells expressing recombinant human OX1R or OX2R (Kb = 11 nM for both). It decreases locomotor activity in rats during the dark cycle when administered at a dose of 10 mg/kg. Filorexant (0.5 mg/kg) reduces the time spent awake and decreases the latency to slow-wave sleep stage 1 (SWS1) and SWS2, but not rapid eye movement (REM) sleep, in dogs. It increases the duration of SWS2, but not SWS1 or REM sleep, in the same model. | | Uses | Filorexant is a selective dual orexin receptor antagonist with potent sleep-promoting properties. It has advanced into phase II clinical trials for the treatment of insomnia. |
| | MK 6096 Preparation Products And Raw materials |
|